Certain piperazinyl and piperidinyl urea compounds are useful as FAAH
inhibitors. Such compounds may be used in pharmaceutical compositions and
methods for the treatment of disease states, disorders, and conditions
mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the
compounds may be administered to treat, e.g., anxiety, pain,
inflammation, sleep disorders, eating disorders, or movement disorders
(such as multiple sclerosis).